Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Original Article

Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs

Authors: Mandeep S. Sawhney, Heather McDougall, Douglas B. Nelson, John H. Bond

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Abstract

Aim

To determine the effect of anticoagulants and antiplatelet medications on the positive-predictive-value of fecal occult blood test (FOBT).

Methods

All patients who underwent a colonoscopy at our institution from 1995 to 2006 for a positive FOBT were identified. Medical records were searched, and patients were stratified into five groups selected a priori: low-dose aspirin, NSAIDs, warfarin, clopidogrel, or controls. The positive-predictive-value of FOBT for advanced colonic neoplasia was computed for each group.

Results

During the study period, 1,126 patients underwent colonoscopy for a positive FOBT and met entry criteria. The average age of study participants was 69 years and most were men. The positive-predictive-value of FOBT for advanced colon neoplasia was significantly higher in the control group (30.5%) when compared to those on low-dose aspirin (20.5%; p = 0.003), NSAIDs (19.7%; p = 0.003), clopidogrel (7.3%; p = 0.002), or warfarin (20%; p = 0.05). The positive-predictive-value of FOBT was significantly lower for those on clopidogrel than those on low-dose aspirin (p = 0.04) and NSAIDs (p = 0.05), but not warfarin (p = 0.08). The positive-predictive-value for FOBT was similar for those on aspirin, NSAIDs, and warfarin. There was a linear trend between the number of number of positive FOBT cards and prevalence of advanced colon neoplasia (p = 0.01).

Conclusion

Anticoagulants and antiplatelet medications lower the positive-predictive-value of FOBT for advance colonic neoplasia and should be stopped if clinically feasible prior to stool collection.
Literature
1.
go back to reference Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the US perspective. Am J Gastroenterol. 2006;101:219–221.CrossRefPubMed Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the US perspective. Am J Gastroenterol. 2006;101:219–221.CrossRefPubMed
2.
go back to reference CDC. Increasing use of colorectal cancer tests. Morb Mortal Wkly Rep. 2006;55:308–311. CDC. Increasing use of colorectal cancer tests. Morb Mortal Wkly Rep. 2006;55:308–311.
3.
go back to reference El-Serag H, Petersen L, Hampel H, Richardson P, Cooper G. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006;166:2202–2208.CrossRefPubMed El-Serag H, Petersen L, Hampel H, Richardson P, Cooper G. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006;166:2202–2208.CrossRefPubMed
4.
go back to reference Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560.CrossRefPubMed
5.
go back to reference Ransohoff D, Lang C. Screening for colorectal cancer with the fecal occult blood test: a background paper. Am Coll Physicians. 1997;126:811–822. Ransohoff D, Lang C. Screening for colorectal cancer with the fecal occult blood test: a background paper. Am Coll Physicians. 1997;126:811–822.
6.
go back to reference Lieberman DA, Weiss DG. 380 FtVACSG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560.CrossRefPubMed Lieberman DA, Weiss DG. 380 FtVACSG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560.CrossRefPubMed
7.
go back to reference Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371.CrossRefPubMed Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371.CrossRefPubMed
8.
go back to reference Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMed
9.
go back to reference Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;148:1472–1477.CrossRef Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;148:1472–1477.CrossRef
10.
go back to reference Bond J. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed Bond J. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21.CrossRefPubMed
11.
go back to reference Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95:3250–3258.CrossRefPubMed Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95:3250–3258.CrossRefPubMed
12.
go back to reference Greenberg P, Cello J, Rockey D. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598–604.CrossRefPubMed Greenberg P, Cello J, Rockey D. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598–604.CrossRefPubMed
13.
go back to reference Fleming J, Ahlquist D, McGill D, Zinsmeister A, Ellefson R, Schwartz S. Influence of aspirin and ethanol on fecal blood levels as determined by using the HemoQuant assay. Mayo Clin Proc. 1987;62:159–163.PubMed Fleming J, Ahlquist D, McGill D, Zinsmeister A, Ellefson R, Schwartz S. Influence of aspirin and ethanol on fecal blood levels as determined by using the HemoQuant assay. Mayo Clin Proc. 1987;62:159–163.PubMed
14.
go back to reference Norfleet R. 1, 300 mg of aspirin daily does not cause positive fecal hemoccult tests. J Clin Gastroenterol. 1983;5:123–125.CrossRefPubMed Norfleet R. 1, 300 mg of aspirin daily does not cause positive fecal hemoccult tests. J Clin Gastroenterol. 1983;5:123–125.CrossRefPubMed
15.
go back to reference Kahi C, Imperiale T. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837–841.CrossRefPubMed Kahi C, Imperiale T. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837–841.CrossRefPubMed
16.
go back to reference Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the hemoccult as a screening test in patients taking anticoagulants. Cancer. 1984;54:3054–3058.CrossRefPubMed Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the hemoccult as a screening test in patients taking anticoagulants. Cancer. 1984;54:3054–3058.CrossRefPubMed
17.
go back to reference Bini E, Rajapaksa R, Weinshel E. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586–1592.CrossRefPubMed Bini E, Rajapaksa R, Weinshel E. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586–1592.CrossRefPubMed
18.
go back to reference Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–289.CrossRefPubMed Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–289.CrossRefPubMed
19.
go back to reference van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193–205.PubMed van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193–205.PubMed
20.
go back to reference Ecclissato C, Carvalho AF, Ferraz JG, de Nucci G, De Souza CA, Pedrazzoli J Jr. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis. 2001;33(5):403–406.CrossRefPubMed Ecclissato C, Carvalho AF, Ferraz JG, de Nucci G, De Souza CA, Pedrazzoli J Jr. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis. 2001;33(5):403–406.CrossRefPubMed
Metadata
Title
Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs
Authors
Mandeep S. Sawhney
Heather McDougall
Douglas B. Nelson
John H. Bond
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1150-4

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue